Your shopping cart is currently empty

SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $64 | In Stock | In Stock | |
| 2 mg | $93 | In Stock | In Stock | |
| 5 mg | $156 | In Stock | In Stock | |
| 10 mg | $255 | In Stock | In Stock | |
| 25 mg | $448 | In Stock | In Stock | |
| 50 mg | $662 | In Stock | In Stock | |
| 100 mg | $987 | In Stock | In Stock | |
| 500 mg | $1,980 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $172 | In Stock | In Stock |
| Description | SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment. |
| Targets&IC50 | 5-HT2C receptor:30 μM (EC50), 5-HT1D receptor:0.262 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), 5-HT7 receptor:6.7 μM (EC50), 5-HT1A receptor:2.3 μM (EC50), TAAR1:0.140 μM (EC50), 5-HT2A receptor:10 μM (EC50) |
| In vitro | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
| In vivo | SEP-856 (0.3, 1, and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs. PCP-induced hyperactivity is significantly reduced by SEP-856 (0.3, 1, and 10 mg/kg, orally once). Oral SEP-856 administration (1, 3, and 10 mg/kg) produces a dose-dependent decrease in REM sleep, increase in latency to REM sleep, and increase in cumulative wake (W) time. |
| Synonyms | SEP-856 hydrochloride |
| Molecular Weight | 219.73 |
| Formula | C9H14ClNOS |
| Cas No. | 1310422-41-3 |
| Smiles | Cl.CNC[C@@H]1OCCc2ccsc12 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (250.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (22.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.